NASDAQ:NEUP Neuphoria Therapeutics Q3 2026 Earnings Report $3.47 -0.04 (-1.14%) Closing price 10/2/2026 03:59 PM EasternExtended Trading$3.46 -0.01 (-0.14%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Neuphoria Therapeutics EPS ResultsActual EPS-$0.09Consensus EPS -$0.56Beat/MissBeat by +$0.47One Year Ago EPSN/ANeuphoria Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeuphoria Therapeutics Announcement DetailsQuarterQ3 2026Date5/15/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time8:00AM ETUpcoming EarningsNeuphoria Therapeutics' Q1 2027 earnings is estimated for Monday, October 5, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Neuphoria Therapeutics Earnings HeadlinesContrasting Neuphoria Therapeutics (NASDAQ:NEUP) & Legend Biotech (NASDAQ:LEGN)September 30, 2026 | americanbankingnews.comNeuphoria Therapeutics (NEUP) Set to Post Earnings on MondaySeptember 28, 2026 | americanbankingnews.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Stock Short Interest Falls 61.8%September 27, 2026 | americanbankingnews.comNeuphoria Therapeutics Inc. Reports Earnings Results for the Full Year Ended June 30, 2026September 19, 2026 | marketscreener.comMNeuphoria Therapeutics Inc Ordinary Shares NEUPAugust 14, 2026 | morningstar.comMSee More Neuphoria Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email. Email Address About Neuphoria TherapeuticsNeuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and other metabolic diseases. The company’s research programs are designed to address conditions involving weight management, diabetes and metabolic dysfunction. Neuphoria’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being developed for obesity and related metabolic conditions. The company is also developing DA-1241, an investigational GPR119 agonist intended for metabolic dysfunction-associated steatohepatitis, formerly known as nonalcoholic steatohepatitis, and other metabolic disorders. These programs originated through collaborations and licensing arrangements with Dong-A-related entities. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and adopted the Neuphoria Therapeutics name as its business focus evolved toward metabolic disease therapies. As a clinical-stage company, Neuphoria does not yet have an established portfolio of commercially marketed products. Its programs remain subject to clinical development, regulatory review and potential approval.View Neuphoria Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/28 - 10/02Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes Next Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
